BPC-157
← Back to LibraryCompound Profile
BPC-157 is reviewed here for tissue repair and recovery.
Research Summary
Safety notices, literature searches, limited protocol data
Tissue repair, Injury recovery, Gut support
Target context: VEGFR2; NO
Limited, unclear, or affected by safety flags.
Claims need extra caution because evidence is thin or safety flags apply.
Route(s)
Subcutaneous
Typical dose
250mcg
Dosing window
Morning / Evening
Receptor / target
VEGFR2; NO
Properties
Dopamine Buffer
Pre-mixed
No
How BPC-157 is studied in tissue repair
BPC-157 is mostly discussed around tendon, ligament, muscle, and tissue-repair research.
Achilles Tendon — Tendon Healing
Animal researchStudied in animal research for healing injured tendons.
Knee and Ligaments — Joint Support
Animal researchStudied for repair of soft tissue around joints.
Muscle — Injury Recovery
Animal researchStudied for how damaged muscle and surrounding tissue may recover.
Injury Area — Blood Flow and Repair
Lab and animal researchStudied for tissue repair and blood-vessel response after injury.
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-6 | 250mcg twice daily | Systemic Protocol. Administered subQ in the abdomen. Affects the entire body's inflammatory response. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative: Localized Injection
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-6 | 250mcg - 500mcg twice daily | Administered subQ as close to the injury site as safely possible (e.g., skin above the knee). |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative: Injury Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 500mcg-1.5mg 2-3x daily | Inject as close to the injury site as safely possible. Can extend beyond 8 weeks if needed, but monitor for diminishing returns after week 8. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | FDA safety-risk context or unapproved compounded-use warning is attached to this entry; no FDA-approved human label was identified for this compound/page context. |
|---|---|
| Where studied | Studied mainly in wound, tendon, ligament, gut, inflammation, angiogenesis, and tissue-repair models; human evidence varies widely by compound. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: VEGFR2; NO. Route(s): Subcutaneous. Dosing window on page: Morning / Evening. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty. |
Source-linked findings
- BPC-157 has mechanistic and animal literature in tendon, ligament, gut, angiogenesis, nitric-oxide, and tissue-repair models.
- FDA has flagged BPC-157 in a bulk-substance safety-risk context; no FDA-approved human label or validated human dosing regimen was identified.
- FDA lists BPC-157 among withdrawn nominated bulk substances with potential significant safety risks and limited safety information for proposed routes.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-6, 250mcg twice daily; Alternative: Localized Injection: Weeks 1-6, 250mcg - 500mcg twice daily.
- Key limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty.
- Monitor injury diagnosis, rehab loading, infection, anticoagulant use, abnormal vessel growth, cancer history, and injection-site sterility.
Selected medical sources
Independent evidence
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Active malignancy: BPC-157's pro-angiogenic mechanism (VEGFR2 upregulation) directly promotes tumor vascularization; contraindicated in any active cancer regardless of type.
- History of any cancer: the theoretical risk of stimulating residual or dormant tumor cells via angiogenesis warrants caution; assess risk-benefit with oncology history carefully.
- History of severe or recurrent histamine reactions: BPC-157 modulates mast cell activity and NO pathways that intersect with histamine signaling; subjects with mast cell activation syndrome (MCAS) or confirmed histamine intolerance require extra caution.
- Subjects currently on anticoagulant or antiplatelet therapy: BPC-157 has potential coagulation and vascular function effects; additive risk with blood thinners warrants monitoring.
- Autoimmune disorders: BPC-157's immune modulatory effects carry theoretical risk of unpredictable immune activation with chronic use; use with caution in subjects with active autoimmune conditions.
- Pregnancy: no human safety data; avoid.
- Breastfeeding: no human safety data; avoid.
- Known hypersensitivity to BPC-157 or any formulation excipients.
- Subjects receiving corticosteroid therapy: corticosteroids (e.g., prednisone) can decrease the effectiveness of BPC-157 and are identified as an interaction in clinical monograph literature.
- Proliferative vascular disorders: subjects with arteriovenous malformations, uncontrolled neovascularization, or other pathological vessel growth syndromes.
- Severe cardiovascular disease with labile blood pressure: BPC-157's NO-mediated vasodilatory effects may cause blood pressure fluctuations.
- Pediatric use: no safety data established.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Lethargy or mild fatigue: the most commonly reported adverse effect; onset typically within the first 1-7 days; likely related to initial inflammatory modulation and systemic healing signal activation; self-resolving.
- Nausea and abdominal discomfort: reported in clinical monograph data; mild; particularly in first days of use.
- Injection site reactions: redness, swelling, irritation at subcutaneous injection site; rotate administration sites.
- Dizziness and headache: vasodilation-related from NO-pathway activation and angiogenic effects.
- Flushing or sensations of heat/cold: NO-mediated vasodilation; transient.
- Sleep disturbances: reported anecdotally and in compounded preparation monograph; onset within the first week; self-resolving.
- Appetite changes: mild; may increase or decrease appetite during early weeks.
- Anhedonia: reported by a small subset of highly sensitive individuals; associated with dopamine buffering effect; temporary during initial cycle days.
- Blood pressure changes: downward pressure changes from NO-mediated vasodilation; monitor in subjects with hypotension.
- Overproduction of nitric oxide (theoretical at very high doses): supraphysiologic NO levels can cause hypotension, oxidative stress, and cellular toxicity; at standard doses this is not a practical concern.
- Pathologic angiogenesis: serious but rare; pro-angiogenic properties that accelerate healing in normal tissue could theoretically support aberrant vessel formation in pathological contexts.
- Changes in coagulation or vascular response: potential influence on clotting pathways; particularly relevant when stacking with other angiogenic or vasodilatory compounds.
- Immune modulation effects: with chronic use at high doses; the magnitude and direction of immune activation are not fully characterized in humans.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: